Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study

Fig. 2

(A) Serum KL-6 levels before and after NTB treatment. (B) Differences in serum KL-6 level changes between the NTB group and the NTB + IS group. (C) Association between changes in serum KL-6 levels (U/mL) and changes in FVC (%) is being examined. KL-6, Krebs von den Lungen-6; FVC, Forced Vital Capacity; NTB, Nintedanib; IS, Immunosuppressive Agents. For statistical analyses, *p < 0.05, **p < 0.01. P-value: Wilcoxon signed rank test, Wilcoxon rank sum test

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us